Anushka Bhaskar
Biographic Data
| ID | 6070872 |
|---|---|
| NAME | Anushka Bhaskar |
| GIVEN NAMES | Anushka |
| FAMILY NAME | Bhaskar |
| SIGNATURE | BHASKAR A |
| AFFILIATIONS | Jay Chandra is with Harvard Medical School, Harvard University, Boston, MA. Marie-Laure Charpignon and Munther A. Dahleh are with the Institute for Data, Systems, and Society, Massachusetts Institute of Technology, Cambridge. Anushka Bhaskar and Andrew Therriault are with the Department of Government, Harvard University, Cambridge. Yea-Hung Chen is with the Department of Epidemiology and Biostatistics, University of California, San Francisco. Alyssa Mooney is with the Institute for Health Policy Studies,... |
| ORCID | 0000-0002-6018-9058 |
| VERIFIED | Yes |
| TOTAL WORKS | 4 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 4 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2023 |
| LATEST PUBLICATION YEAR | 2024 |
| H-INDEX | 0 |
Use, Spending, and Prices of Adalimumab Following Biosimilar Competition
This cross-sectional study examines the use, spending, and prices of adalimumab biosimilars in the first year of market competition in the US
Excess Fatal Overdoses in the United States During the Covid-19 Pandemic by Geography and Substance Type
Objectives. To assess heterogeneity in pandemic-period excess fatal overdoses in the United States, by location (state, county) and substance type. Methods. We used seasonal autoregressive integrated moving average (SARIMA) models to estimate counterfactual death counts in the scenario that no pandemic had occurred. Such estimates were subtracted from actual death counts to assess the magnitude of pandemic-period excess mortality between March 20…
Securing the Trustworthiness of the FDA to Build Public Trust in Vaccines
The Covid‐19 pandemic highlighted the need to examine public trust in the U.S. Food and Drug Administration (FDA) vaccine approval process and the role of political influence in the FDA's decisions. Ensuring that the FDA is itself trustworthy is important for justifying public trust in its actions, like vaccine approvals, thereby promoting public health. We propose five conditions of trustworthiness that the FDA should meet when it reviews vaccin…
What Should Be Clinicians’ Roles in Regulatory Assessment of Prospective Interventions’ Risks of Exacerbating Inequity
When there is an evidence base that could be used credibly to justify expedited US Food and Drug Administration review, emergency use authorization, or approval, interventions-in-development must be evaluated in terms of their possible downstream influence on public trust and confidence in regulatory processes during a national public health crisis. When regulatory decisions express overconfidence about a prospective intervention's success, there…
No prominent works on this page.
Securing the Trustworthiness of the FDA to Build Public Trust in Vaccines
The Covid‐19 pandemic highlighted the need to examine public trust in the U.S. Food and Drug Administration (FDA) vaccine approval process and the role of political influence in the FDA's decisions. Ensuring that the FDA is itself trustworthy is important for justifying public trust in its actions, like vaccine approvals, thereby promoting public health. We propose five conditions of trustworthiness that the FDA should meet when it reviews vaccin…
What Should Be Clinicians’ Roles in Regulatory Assessment of Prospective Interventions’ Risks of Exacerbating Inequity
When there is an evidence base that could be used credibly to justify expedited US Food and Drug Administration review, emergency use authorization, or approval, interventions-in-development must be evaluated in terms of their possible downstream influence on public trust and confidence in regulatory processes during a national public health crisis. When regulatory decisions express overconfidence about a prospective intervention's success, there…
Use, Spending, and Prices of Adalimumab Following Biosimilar Competition
This cross-sectional study examines the use, spending, and prices of adalimumab biosimilars in the first year of market competition in the US
Excess Fatal Overdoses in the United States During the Covid-19 Pandemic by Geography and Substance Type
Objectives. To assess heterogeneity in pandemic-period excess fatal overdoses in the United States, by location (state, county) and substance type. Methods. We used seasonal autoregressive integrated moving average (SARIMA) models to estimate counterfactual death counts in the scenario that no pandemic had occurred. Such estimates were subtracted from actual death counts to assess the magnitude of pandemic-period excess mortality between March 20…
Medicine (4 works) · Public health (3 works) · Business (2 works) · Economics (2 works) · Health Systems, Economic Evaluations, Quality of Life (2 works) · Actuarial science (1 works) · Adalimumab (1 works) · Agency (philosophy) (1 works) · Biosimilar (1 works) · Biosimilars and Bioanalytical Methods (1 works)